Goodwin Procter·IP / PATENT

BMS and Ono Sue Amgen Over Opdivo Biosimilar

Bristol-Myers Squibb and Ono Pharmaceutical have filed a BPCIA patent-infringement complaint against Amgen in Delaware, asserting seven patents against its proposed biosimilar of the cancer drug Opdivo.

bpciapatent-litigationbiosimilarspharmabristol-myers-squibbamgennivolumab

Read the original firm alert → Wednesday, September 23, 2026

Stay ahead

Join the digest.

One email when the daily AmLaw 100 briefing ships. No noise, no pitch decks — just the grade 4–5 signal.